Homolog

A homolog is a compound belonging to a series in which each member differs from the next by a fixed structural unit — most often a methylene group (–CH₂–), adding one carbon and two hydrogens to a chain or ring.

The word comes from the Greek for same kind. Homologs share the same core scaffold and functional groups; only the size of one chain or substituent changes. Because the change is incremental and predictable, homologous series are a foundational concept in organic chemistry, used to understand how small structural steps produce systematic shifts in a molecule's properties.

How it works · its role

Each added methylene unit raises the molecular weight slightly and, in most cases, increases the compound's lipophilicity — its affinity for fatty, non-polar environments like cell membranes and fatty tissue. More lipophilic molecules tend to cross the blood–brain barrier more readily and linger longer in the body.

At the receptor level, the added length or bulk can improve or worsen the geometric fit between a molecule and its binding site. This means potency, duration, and even receptor selectivity can shift in a graded, sometimes predictable way as the chain grows — though the relationship is rarely perfectly linear, and at some point added length begins to hurt rather than help binding.

Lipophilicity also affects onset and elimination. Compounds later in a homologous series are generally slower to clear, which contributes to longer-lasting effects.

Relevance to substances & effects

Homology is especially prominent in the synthetic cannabinoid class. Many series are defined by the length of an alkyl chain attached to a common scaffold; moving from a butyl to a pentyl to a hexyl chain can dramatically increase binding affidity at cannabinoid receptors, producing stronger and longer-lasting effects from structurally similar molecules.

Tryptamine psychedelics offer another clear example. DMT, DET, and DPT share the same indole core; each adds a carbon to the N-alkyl chains, shifting pharmacokinetics and potency in a way researchers have studied systematically.

Homology also matters in the regulatory and harm-reduction context. Because homologs share a scaffold but differ by a single unit, a newly synthesised homolog may not yet appear on a controlled-substances list even when closely related compounds are scheduled. This structural stepping is a recurring pattern in the emergence of novel psychoactive substances, which is why forensic chemists and regulators increasingly use structural analog laws and class-based scheduling rather than compound-by-compound controls.